REGN
A rare disease, a rare win
Regeneron dropped new 84-week data from its Phase 3 OPTIMA trial for Pasatru, the company’s recently approved treatment for fibrodysplasia ossificans progressiva, or FOP. That’s the ultra-rare disorder nicknamed “stone man disease,” where soft tissue slowly turns into bone like your body is running a very bad software update.
Why the market cared
The headline here isn’t just that the drug worked — it’s that the effect stuck around. Regeneron said Pasatru continued to halt new abnormal bone growth and cut flare-ups through week 84, with no new heterotopic ossification lesions seen in the treatment group from week 56 to 84. In biotech, durability is the difference between “nice presentation” and “this could actually be a business.”
A little extra runway
The safety profile was said to remain generally manageable, even with a dose-dependent increase in skin and soft tissue infections. The bigger investor question now is whether Regeneron can keep building this franchise and broaden the market; the company says it plans to start OPTIMA 2 in children and adolescents later this year.
Big picture: rare-disease drugs can look small on a spreadsheet until one becomes the kind of steady cash-flow machine that investors love to forget is biotech at all — still risky, just with a much shinier story.